Dong-A ST announced on the 19th that it has launched the autoimmune disease treatment 'IMULDOSA' in the United States.
IMULDOSA is a treatment for inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and it is a biosimilar of Janssen's Stelara (ingredient name ustekinumab). The original drug Stelara recorded sales of $21.552 billion (approximately 29.9357 trillion won) last year.
Sales of IMULDOSA will be handled by the global pharmaceutical company Intas, based in India, and Accord BioPharma in the United States. Dong-A ST signed a global technology transfer agreement for IMULDOSA with Intas in 2021. IMULDOSA has been launched in a total of 14 countries, including Germany, the UK, and Spain, and has obtained product approval in the Middle East, including Saudi Arabia, Qatar, and the United Arab Emirates.
A representative of Dong-A ST said, "With the launch of IMULDOSA in the United States following Europe, we are accelerating our entry into the global market," and noted, "We will do our best to ensure that IMULDOSA establishes itself as an effective treatment option for patients worldwide."